Mesenchymal stem cells were treated Type II diabetes in the clinical trials

Researchers from Diabetes Research Institute, Miami, US conducted successful clinical trials of diabetes therapy using mesenchymal stem cells. The results were published on July 7 in the journal Diabetes Care.

The study included 61 adult patients with type II diabetes. Trial participants were divided into two groups: the first group received an intravenous injection of allogeneic mesenchymal stem cells (MSCs) of various concentrations; second – placebo.

At 12 weeks after a single injection of the negative effects of allogeneic cells, including the presence of antibodies anti-HLA, don’t observed. Furthermore, in the first group showed a significant decrease in HbA1c compared to placebo.

“This study was preliminary. In addition, the method proved to be safe, he also had a positive effect, “- says lead author Jay Skyler, a professor of medicine, pediatrics and psychology Diabetes Research Institute.
He also noted that the mesenchymal stem cells are now being studied with great interest in the world in many areas of medicine, as well as anti-inflammatory agent.

“Diabetes mellitus type II is accompanied by inflammatory processes, which can be reduced with the help of MSC. By reducing of inflammation improves the function of beta cells, resulting in a reduction of insulin resistance, “- says Skyler.

In all patients participating in the study had been diagnosed with type II diabetes with HbA1c 7.0 percent or more above the norm, despite the passage of therapy aimed at reducing the level of glucose.

None of the subjects were not found HLA antibodies to the donor MSCs. Also, there was a marked reduction in HbA1c, with prolonged time, all patients in the group, regardless of the concentration of injection.

Positive results have inspired the team to full-scale clinical trial, which will begin soon.